GALACTIC-1: Galectin-3 inhibition in idiopathic pulmonary fibrosis (IPF) – rationale, objectives and design of a 52-week, Phase IIb study of GB0139

T. Maher (Los Angeles, United States), M. Wijsenbeek (Rotterdam, Netherlands), N. Hirani (Edinburgh, United Kingdom), B. Lindmark (Copenhagen, Denmark), D. Phung (Copenhagen, Denmark), A. Mac Kinnon (Copenhagen, Denmark), T. Sethi (Copenhagen, Denmark), V. Aslanis (Copenhagen, Denmark), C. Mc Clinton (Copenhagen, Denmark), E. Andersen (Copenhagen, Denmark), H. Schambye (Copenhagen, Denmark), J. Wang-Jairaj (Copenhagen, Denmark)

Source: International Congress 2022 – Promising new approaches in idiopathic interstitial pneumonias

Session: Promising new approaches in idiopathic interstitial pneumonias
Session type: Thematic Poster
Number: 1932

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Maher (Los Angeles, United States), M. Wijsenbeek (Rotterdam, Netherlands), N. Hirani (Edinburgh, United Kingdom), B. Lindmark (Copenhagen, Denmark), D. Phung (Copenhagen, Denmark), A. Mac Kinnon (Copenhagen, Denmark), T. Sethi (Copenhagen, Denmark), V. Aslanis (Copenhagen, Denmark), C. Mc Clinton (Copenhagen, Denmark), E. Andersen (Copenhagen, Denmark), H. Schambye (Copenhagen, Denmark), J. Wang-Jairaj (Copenhagen, Denmark). GALACTIC-1: Galectin-3 inhibition in idiopathic pulmonary fibrosis (IPF) – rationale, objectives and design of a 52-week, Phase IIb study of GB0139. 1932

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.